A mother's perspective on Sarepta's gene therapy halt

A mother's perspective on Sarepta's gene therapy halt

STAT reporters discuss how Sarepta's gene therapy halt is affecting families of children with Duchenne muscular dystrophy.

Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs

Sarepta has temporarily paused shipments of Elevidys, its FDA-approved treatment for Duchenne muscular dystrophy. In this episode of GEN‘s Touching Base, we discuss the company’s response to the tragedies associated with its DMD therapy as well as with a new therapy for limb-girdle muscular dystrophy. Also in this episode, big updates from AstraZeneca including a $50 billion investment in U.S. manufacturing and R&D, a heartwarming story about pr…

Sarepta's crisis week: How questions over patient deaths put the biotech's future in jeopardy

The call came just days before a 7-year-old boy was set to receive Sarepta Therapeutics' gene therapy Elevidys for his deadly disease. His family, which in May received a Duchenne muscular dystrophy diagnosis, had clung ...

Recapping the Sarepta Saga—And Implications for Industry

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation and market access.